Cancer medicine is a challenging field with an increasing range of promising therapies and combinations. Increasingly, personalised medicine shows promise to improve cancer outcomes – response, symptom control, survival and cure. However, optimal dosing is an under‐appreciated aspect of personalised anticancer therapy, with few clinical trials addressing this specific issue. This position paper aims to inform various health professionals about the principles that guide anticancer drug dose selection and modifications. We discuss the available evidence base for personalised dosing, as well as the professional judgement required by experienced oncology physicians to determine the most appropriate dose for each patient. We provide nine steps t...
BACKGROUND: Oral anticancer drugs show a high interpatient variability in pharmacokinetics (PK), lea...
BACKGROUND: Oral anticancer drugs show a high interpatient variability in pharmacokinetics (PK), lea...
Molecular targeted therapies with tyrosine kinase inhibitors (TKIs) have been a recent breakthrough ...
Cancer medicine is a challenging field with an increasing range of promising therapies and combinati...
Targeted therapies have been a major breakthrough in the treatment of cancer. With the introduction ...
There are still a number of limitations to the full use of therapeutic drug monitoring (TDM) to opti...
In recent years, drug development in oncology switched focus from conventional cytotoxic drugs to ta...
The treatment of cancer is increasingly personalized, with dose optimization being an important fact...
In the current era of precision medicine in oncology, the tailoring of treatment of patients on the ...
As all anti-cancer drugs are of narrow therapeutic window so dose individualization is required to b...
Most anticancer agents exhibit a narrow therapeutic index, i.e., a small change in plasma concentrat...
The traditional approach to dosing anticancer drugs is to ad-minister a standard starting dose, whic...
Cancer is a global health problem. While there have been some major advances in the treatment of sol...
Drug therapy is an important component of the treatment and prevention of diseases. A drug is admini...
Drug developers in oncology indication has been struggling with a low probability of success for dec...
BACKGROUND: Oral anticancer drugs show a high interpatient variability in pharmacokinetics (PK), lea...
BACKGROUND: Oral anticancer drugs show a high interpatient variability in pharmacokinetics (PK), lea...
Molecular targeted therapies with tyrosine kinase inhibitors (TKIs) have been a recent breakthrough ...
Cancer medicine is a challenging field with an increasing range of promising therapies and combinati...
Targeted therapies have been a major breakthrough in the treatment of cancer. With the introduction ...
There are still a number of limitations to the full use of therapeutic drug monitoring (TDM) to opti...
In recent years, drug development in oncology switched focus from conventional cytotoxic drugs to ta...
The treatment of cancer is increasingly personalized, with dose optimization being an important fact...
In the current era of precision medicine in oncology, the tailoring of treatment of patients on the ...
As all anti-cancer drugs are of narrow therapeutic window so dose individualization is required to b...
Most anticancer agents exhibit a narrow therapeutic index, i.e., a small change in plasma concentrat...
The traditional approach to dosing anticancer drugs is to ad-minister a standard starting dose, whic...
Cancer is a global health problem. While there have been some major advances in the treatment of sol...
Drug therapy is an important component of the treatment and prevention of diseases. A drug is admini...
Drug developers in oncology indication has been struggling with a low probability of success for dec...
BACKGROUND: Oral anticancer drugs show a high interpatient variability in pharmacokinetics (PK), lea...
BACKGROUND: Oral anticancer drugs show a high interpatient variability in pharmacokinetics (PK), lea...
Molecular targeted therapies with tyrosine kinase inhibitors (TKIs) have been a recent breakthrough ...